Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.
|Videos|June 28, 2017
Dr. Eskelund Discusses TP53 Mutated Mantle Cell Lymphoma
Author(s)Christian Winther Eskelund, MD
Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses TP53-mutated mantle cell lymphoma (MCL).
Advertisement
Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses TP53-mutated mantle cell lymphoma (MCL).
TP53 has been associated with poor outcomes in many different cohorts of MCL, says Eskelund.
Eskelund suggests that TP53 status should be measured upfront in patients who are diagnosed with MCL. As clinical trials become available, treating physicians should highly consider entering their patients onto them.
Advertisement
Related to this article
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
3
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5